Serum biomarkers in Duchenne muscular dystrophy: a leap toward precision diagnostics
Abstract
I was interested to read the article by Dowling et al.1 in the European Journal of Translational Myology, where the authors provide a comprehensive review of serum biomarkers for Duchenne Muscular Dystrophy (DMD), a devastating early-onset muscle wasting disease. The emphasis of research on liquid biopsy-based approaches, with the application of Mass Spectrometry (MS)-based proteomics for the identification of novel biomarkers like carbonic anhydrase CA3, fatty acid binding protein FABP3, and titin fragments, represents a revolutionary step towards minimally invasive diagnostics. As a neurologist and clinical pharmacologist working in Uganda, where diagnosis of DMD is delayed owing to the limited access to invasive tests, I find the prospects of these biofluid-based markers not only intriguing but also of immense worth in advancing precision medicine in resource-poor settings. [...]
References
- 1. Dowling P, Negroni E, Trollet C, et al. Serum protein biomarker signature of Duchenne muscular dystrophy. Eur J Transl Myol 2025;35:13956. DOI: https://doi.org/10.4081/ejtm.2025.13956
- 2. Hathout Y, Seol H, Han MH, et al. Clinical utility of serum biomarkers in Duchenne muscular dystrophy. Orphanet J Rare Dis 2016; 11:9. DOI: https://doi.org/10.1186/s12014-016-9109-x
- 3. McNally EM, Mann DL, Pinto Y, et al. Dystrophin-glycoprotein complex and heart failure in Duchenne muscular dystrophy. Nat Rev Cardiol 2021;18:93–108.
- 4. Aartsma-Rus A, Corey DR. The 10th oligonucleotide therapy approved: viltolarsen for treatment of Duchenne muscular dystrophy. Nucleic Acid Ther 2020;30:272–6. DOI: https://doi.org/10.1089/nat.2020.0845
- 5. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018;17:251–67. DOI: https://doi.org/10.1016/S1474-4422(18)30024-3
- 6. Turgeman T, Rosenberg T, Klein A, et al. Anti-fibrotic therapies for Duchenne muscular dystrophy. Matrix Biol 2023;119:133–47.
- 7. Mendell JR, Sahenk Z, Lehman K, et al. Assessment of systemic delivery of rAAVrh74.MHCK7. micro-dystrophin in boys with Duchenne muscular dystrophy. JAMA Neurol 2020;77:1122–31. DOI: https://doi.org/10.1001/jamaneurol.2020.1484
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.